- Market Capitalization, $K 159,677
- Shares Outstanding, K 62,865
- Annual Sales, $ 0 K
- Annual Income, $ 47,420 K
- 60-Month Beta 1.31
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book N/A
|Period||Period Low||Period High||Performance|
| || |
+1.25 (+97.66%)since 11/03/23
| || |
-0.90 (-26.24%)since 09/05/23
| || |
+0.50 (+24.63%)since 12/05/22
Omeros: Q3 Earnings Snapshot
Omeros: Q2 Earnings Snapshot
The clinical-stage biopharmaceutical released trials data through a presentation.
Omeros: Q1 Earnings Snapshot
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2023, on Tuesday, May 9, 2023, after the market closes....
Omeros Corporation (Nasdaq: OMER) today announced positive results from a pre-specified interim analysis of its ongoing Phase 1b clinical trial of OMS906, the company’s lead MASP-3 inhibitor, in complement-inhibitor-naïve...
EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END
/PRNewswire/ -- Alcohol consumption and drug abuse have become public health concerns worldwide. Governments are working on ways to detect any symptoms of...
Omeros Corporation (Nasdaq: OMER) today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to develop Omeros’ lead...
Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day.
|Invesco Nasdaq Future Gen 200 ETF|
|DJ Select Microcap ETF FT|
|Micro-Cap Ishares ETF|
|GS Activebeta U.S. Small Cap Equity ETF|
|Oppenheimer Russell 2000 Multifactor ETF|